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1. Introduction 
Methylphenidate is one of the drugs that has been shown to elicit behavioral sensitization 
(1). Methylphenidate was synthesized by Ciba chemist Leandro Panizzon. His wife, 
Marguerite, had low blood pressure and would take the drug as a stimulant before playing 
tennis. He named the substance Ritaline, after his wife's nickname, Rita (2). 
Its use has increased rapidly over the years and currently the drug is often prescribed for a 
large span of ages from childhood through adolescence and up to adulthood, thus 
facilitating the study of its effect on human physiology. Therefore, it there is an abundance 
of opportunities to study its various effects on the human organism.  
Methylphenidate is a piperidine derivative, structurally related to amphetamines and acts as 
a CNS stimulant. Methylphenidate has been widely used since 1937 for numerous 
indications including attention deficit hyperactivity disorder (ADHD), narcolepsy, cataplexy 
(3) and conduct disorder (4) in children and adolescents as well as adults (4). Although it 
has been indicated for ADHD since 1957 it has gained widespread use during the last two 
decades (5). Methylphenidate was found to affect brain sterol metabolism in mice by 
inhibition of the incorporation of its precursors, acetate and glucose, into the brain and by 
reduction of the brain’s sterol levels (6). This reduction was found to occur within 24 hours 
in the neuronal cellular membrane, the site of methylphenidate’s action (6).  
2. Risk factors of atherosclerosis and cardiovascular disease 
Atherosclerosis is a slowly progressive process starting at a young age (7). Therefore, many 
effective measures are taken early in life to prevent future cardiovascular disease 
worldwide, the most important being the awareness of a proper lifestyle, including physical 
activity, a proper diet, and abstaining from drugs and habits that may increase the 
likelihood of atherosclerosis through the development of different risk factors (e.g., 
hyperlipidemia). 
Several reports (8-9) found no association between prolonged administration (1 to 4 years) 
of methylphenidate to hyperactive boys regarding hematopoietic, endocrine (including 
blood glucose levels), hepatic or cardiovascular function. This is unlike the 
hypercholesterolemic effect of various psychotropic medication (see below) that can cause 
www.intechopen.com
 
Current Directions in ADHD and Its Treatment 
 
186 
hypercholesterolemia secondary to cholestasis(10). It is known that cholestasis can cause 
hypercholesterolemia (10). Serum cholesterol appeared to be dominantly affected by 
lipoprotein X. Intra-hepatic cholestasis leading to reflux of bile lipids into the blood stream 
and subsequent formation of lipoprotein X appears to be the mechanism (11) underlying 
this phenomenon . 
2.1 Methylphenidate's toxicity 
The therapeutic use of methylphenidate for the management of ADHD in children is 
constantly increasing. As therapeutic use this increases the risk of unintentional overdoses, 
medication errors, and intentional overdoses caused by abuse, misuse, or suicide attempts. 
Side effects, which include nervousness, headache, insomnia, anorexia, and tachycardia 
increase linearly with dose (3). Clinical manifestations of overdose include agitation, 
hallucinations, psychosis, lethargy, seizures, tachycardia, dysrhythmias, hypertension, and 
hyperthermia. Hepatotoxicity was reported in rodents (11). A possible mechanism is 
inhibition of cytochrome p-450 (12). There are few reports about different organ failure. 
These were manifested by abnormal liver function enzymes, poor urine output, 
hypotension, tachypnea, tachycardia, abnormal blood gases, rising serum BUN and 
creatinine, and hyperactive deep-tendon reflexes (13). Despite its abuse potential, there is 
disagreement regarding the extent to which methylphenidate is being diverted from 
legitimate use to abuse in children and adolescents.  
Gontkovsky et al (14) reported a decrease of 26% in serum glucose values after 
methylphenidate initiation in a patient post- cerebellar tumour resection.  
Being a neurostimulant, the possible linkage of methylphenidate to the cardiovascular 
system was investigated. The data are controversial. Samuels et al. (8) investigated the effect 
of methylphenidate on blood pressure. Their study provided evidence for a possible 
negative cardiovascular effect of the stimulant medication on children with ADHD. Vitiello 
(15) did not find clinically significant changes in cardiovascular function in the majority of 
cases investigated. However, Langendijk et al (16) in their review show an increase in blood 
pressure and heart rate among adults treated with methylphenidate as being a risk factor for 
cardiovascular event, and Rapport et al (17) described a transient increase in blood pressure 
and heart rate among children treated by methylphenidate for ADHD. This was dose 
dependent and easily rectified with dosage adjustment. Spivak et al (18) reported a 
thrombocythopenia and decreased levels of norepinephrine, dopa and serotonine in 
children treated for three months with methylphenidate which means inhibitory impact on 
platelets activation.  
Heart failure due to idiopathic dilated cardiomyopathy (DCM) is uncommon in young 
people. Cocaine and amphetamines are known to have caused dilated cardiomyopathy (19). 
There are very few reports linking methylphenidate therapy to DCM. Two reports from 
Norway described serious cardiomyopathy in young patients treated with methylphenidate 
(20-21). One of them was severly obese (BMI-40). An obesity-linked susceptibility to the 
toxic effect of methylphenidate could, therefore, play a role in the development of DCM in 
this patient. This is remarkable especially with regards to the short (one year) duration of 
the treatment. With a BMI of 40 the above mentioned patient had suffered from extreme 
obesity. The hyperdynamic circulation, with increased cardiac output, thought to be a 
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compensatory adaptation to increased adipose tissue may, at the expense of left ventricular 
hypertrophy and remodeling, lead to non ischemic dilated cardiomyopathy in severe obese 
subjects (22, 23). This is, however, unlikely to be the only cause. Human obesity is also 
characterized by sympathetic nervous activation (23). The concern is that methylphenidate 
is the responsible agent. Although the number of patients treated with this drug is high, and 
the reported cardiovascular side effects are few, scientists were concerned about the serious 
long term results this side effect could have on children and young adults. No guidelines are 
available to help identify individuals prone to cardiomyopathy due to central stimulating 
drugs.  
Cardiac adverse effects from methylphenidate have been shown to affect myocardial ultra-
structure in rats. This effect was irreversible after 12 weeks (24, 25). Methylphenidate is a 
drug which stimulates the central nervous action and produce similar effects as 
amphetamines. Both drugs increase synaptic and intracellular norepinephrine and 
dopamine in rodents and baboons (25, 26). For amphetamine the mechanism has been 
shown to trigger both an increased release of catecholamines and blocking their synaptic 
reuptake and degradation (26-27). It is the increase in adrenergic action that is believed to be 
cardiotoxic over time and promote cardiomyopathy (24, 28). This can be understood by the 
observation that, in transgenic mice, myocardial over expression of beta-adrenergic 
receptors was associated with myocyte apoptosis and the development of dilated 
cardiomyopathy (27, 29).  
3. Methylphenidate and dyslipidemia 
In many cases methylphenidate is prescribed for extended periods of time, usually starting 
from childhood or adolescence. Therefore, in the long run any metabolic consequence of the 
treatment might be deleterious, especially when atherosclerosis is considered. From this 
perspective, it seemed essential to substantiate the potential of methylphenidate to affect 
lipid profile. In order to evaluate this, we first looked into the possibility that other 
psychotropic drugs have an impact on cholesterol and tryglicerides. 
Hyperlipidemia is one of the major risk factors for atherosclerosis and cardiovascular diseases 
(30, 31). The causes of lipid metabolism abnormalities are mainly genetic. Established causes 
for secondary dyslipidemia include inappropriate lifestyle, liver disease, renal disease and 
thyroid disease (7, 9). The various drugs that are known to affect lipid metabolism include 
hormones (glucocorticoids, estrogens and androgens), beta-blockers, and diuretics (3, 7, 32-40). 
Several psychotropic drugs were reported to cause secondary hyperlipidemia, especially 
carbamazepine, phenobarbital, tricyclic antidepresants (in particular amitriptyline), second-
generation antipsychotic medication, mainly olanzapine but also risperidone and ziprasidone. 
In their extensive review Ruetsch and co-writers elaborate on weight gain induced by 
psychotropic medications (38). According to this and many other reports weight gain is the 
mainstay of the psychotropic pharmacological induced hyperlipidemia. Weight gain was 
found to induce dyslipidemia in correlation with dosage and duration of treatment (38). In 
addition to increased total cholesterol and low-density lipoprotein cholesterol (LDL-c) there 
was also a tendency to elevate blood pressure levels and thus enhance the impact on the 
development of atherosclerosis (31-34)., These can aggravate health risks, including higher rate 
of coronary heart desease, ischemic stroke due to impaired glucose tolerance, diabetes 
mellitus, dyslipidemia, respiratory problems.  
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Weight gain appears to be most prominent with some mood stabilizers (e.g. lithium, 
valproate, 34-38). According to current concepts, appetite and feeding are regulated by a 
complex of neurotransmitters, neuromodulators, cytokines and hormones interacting with 
the hypothalamus, including leptin and tumor necrosis factor system (37-39). The 
pharmacologic mechanisms underlying weight gain are presently poorly understood: 
possibly the various activities at some receptor systems may induce it, but also genetic 
predisposition plays an important role. In addition the insulin-like effect of lithium is well 
known.  
Weight gain has been described since the discovery and the use of the first psychotropic 
drugs, but seems to intensify especially with some of the second generation antipsychotic 
medications. Understanding of the side effects of psychotropic drugs, including their 
metabolic consequences (weight gain, diabetes, dyslipidemia) is essential in order to avoid, 
firstly, a risk of lack of compliance with the ensuing risk of relapse and re-hospitalization, 
and secondly, the acute, life threatening events (diabetic ketoacidocetosis and non ketotic 
hyperosmolar coma) and long term risk complications of diabetes and overweight (31,37,39).  
Many psychotropic drugs (especially methylphenidate) were designed to be started early in 
childhood in order to improve various target organ, cognitive and neuropsychiatric 
functions. These medications appeared to be very potent and significantly changed life 
quality, which led to their widespread use all over the world (5). This medications are often 
continued for a long periods (years) and may cause unfavorable metabolic effects. Rader 
and Hobbs (40) reported that some of these drugs affect lipid and lipoprotein metabolism 
and increase or decrease atherogenicity.  
Methylphenidate is the most abundantly used medication for the treatment of ADHD in all 
ages worldwide (5). It is well known that methylphenidate has an effect on intracellular 
cholesterol in the brain, but to date its effect on plasma lipid metabolism has been studied to 
a limited extent in clinical setting (6, 41). We recently published the results of a randomized 
study that examined the effect of methylphenidate on blood lipid levels (42). A total of 42 
outpatients with an established diagnosis of ADHD were studied. The baseline 
characteristics of the study group are presented in Table 1. There were 22 males and 20 
females whose median age was 16 years (range 11-31). Table 2 displays the differences in the 
examined parameters before and after a 3 month treatment by methylphenidate. BMI didn't 
change during the study period. Significant decrease was found in total cholesterol, LDL- c 
and tryglicerides levels. Non significant changes were seen in HDL-c, apolipoprotein A and 
apolipoprotein B levels. The changes in Lp (a) unexpectedly turned out to be statistically 
significant. There were no gender- based differences in any of these parameters after 
adjustment according to age, nor any correlations between the lipid parameters. 
This is the first investigation into the impact of methylphenidate on plasma lipid profile and 
atherosclerosis. The results of the current study showed that methylphenidate has a 
significant and positive impact on the lipid and lipoprotein profile with regard to 
atherosclerosis. It significantly decreases total cholesterol, triglycerides and the main 
atherosclerotic lipoproteins, LDL-c and Lp(a). There is no good explanation of lipid 
lowering mechanism. However, in contrast to other psychotropic medication it didn't cause 
weight gain. The possible explanation: amphetamine related agents-(including 
methylphenidate) increase synaptic dopamine by stimulating presynaptic release of the last 
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Variable 
Median 
Lower 
quartlile 
Upper 
quartlile 
Age (years) 16 14 22 
Males 52%   
BMI 22 20 24 
T-Chol(mg/dl) 157 142 179 
HDL-C(mg/dl) 51 45 64 
LDL-C(mg/dl) 93 74 114 
Trigl(mg/dl) 76 58 100 
Apo A(mg/dl) 122 109 137 
Apo B(mg/dl) 71 56 83 
Lp(a)(mg/dl) 23 9 40 
BMI,body mass index ; HDL-C, high density lipoprotein; 
LDL-C, low density lipoprotein; Apo A, apolipoprotein A 
Apo B, apolipoprotein B; Lp (a), lipoprotein (a). 
Table 1. Patient characteristics (n = 42) 
 
Variable Median Lower quartle Upper quartle p*= 
ΔBMI 0 0 0.3 0.24 
Δ T-Chol (mg/dl) -9 -15 -3 0.0002 
Δ HDL-C(mg/dl) 2 0 4 0.1 
Δ LDL-C(mg/dl) -5 -8 1 0.016 
Δ Trigl(mg/dl) -8 -15 -3 0.016 
Δ Apo A(mg/dl) -4. -12 7 0.16 
Δ Apo B(mg/dl) -2 -5. 5 0.6 
Δ Lp(a)(mg/dl) -2 -5 0 0.0007 
ΔnonHDLC(mg/dl) -11 -18 -2 0.0001 
Δ-difference 
* Based on Wilcoxson test. 
Table 2. Differences in lipid profile and BMI parameters before and after the treatment by 
methylphenidate. 
and cause an anorexigenic effect by changes in hypothalamic monoaminergic activity and in 
the anorexigenic cocaine-amphetamine –regulated transcript neuropeptide ( CART) 
expressed in the paraventricular nucleus and hypothalamic perifornical nucleus (43, 44). 
Conclusion: the presented data support some positive effects on lipid profile by decreasing 
total cholesterol, triglycerides, LDL-c and Lp (a). No conclusions could be reached concerning 
atherosclerosis. 
4. Limitations 
These conclusions are tentative because of the large rate of early drop outs from the studies, 
which may limit the validity of the results. The study was performed on a relatively small 
number of patients (42 patients) mostly teenagers. There is not enough data about impact of 
methylphenidate on adult population. The reported short term study, conducted for three 
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months, showed positive effects on lipid profile. However it doesn't allow us to predict 
whether this effect will persist and whether atherosclerosis will develop.  
Further, large, well-designed trials are necessary to establish the different metabolic effects 
of methylphenidate 
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